Hyundai Bioscience Confirms Entry into U.S. FDA Phase 2 Trials for Broad-Spectrum Antiviral ‘XAFTY’ Following 2026 Biotech Showcase Consensus
– UCSD’s Dr. Davey Smith, former ACTIV-2 Protocol Chair, endorses ‘Xafty’ as “The weapon to end the virus war.” – Announces…